JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA - News) announced today that the U.S. District Court for the District of New Jersey has granted Eisai’s motion for a preliminary injunction related to Teva’s tentatively approved Abbreviated New Drug Application (ANDA) to market its generic version of Eisai’s Alzheimer’s treatment Aricept® (Donepezil Hydrochloride) Tablets, 5 mg and 10 mg. The injunction is based on Eisai’s enforcement of U.S. Patent No. 4,895,841 that Teva has asserted is unenforceable. A trial date has not been set.
